The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to successful chimeric antigen receptor (CAR) T cell therapies in solid tumors including glioblastoma multiforme (GBM). To address this issue and improve the efficacy of CAR T cell therapy for GBM, we develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Edward Z., Wang, Xin, Philipson, Benjamin I., Zhang, Qian, Thokala, Radhika, Zhang, Logan, Assenmacher, Charles-Antoine, Binder, Zev A., Ming, Guo-li, O’Rourke, Donald M., Song, Hongjun, Milone, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707011/
https://www.ncbi.nlm.nih.gov/pubmed/36458202
http://dx.doi.org/10.1016/j.omto.2022.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707011/
https://www.ncbi.nlm.nih.gov/pubmed/36458202
http://dx.doi.org/10.1016/j.omto.2022.11.004

Ejemplares similares